Another CKD-Related Anemia Drug Goes Under the Microscope of FDA Advisors

(MedPage Today) -- An FDA advisory panel will weigh in on whether the safety signals of daprodustat in chronic kidney disease (CKD)-related anemia are too risky to recommend the oral agent for approval.
On Wednesday, the FDA's Cardiovascular and...

Source: MedPage Today Public Health - October 25, 2022 Category: American Health Source Type: news